文献速递神经肿瘤

同步与辅助化疗对接受放疗的胶质瘤患者淋巴细胞减少严重程度和持续时间的影响

Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy.
PubMed 文献 · J Neurooncol · 2017-11-16

该回顾性研究分析了2007至2016年接受放疗联合同步和/或辅助化疗的WHO II-III级胶质瘤患者,比较同步与辅助化疗对淋巴细胞减少的影响。同步化疗是急性淋巴细胞减少的主要预测因素,而辅助化疗疗程与12个月时淋巴细胞减少相关。

要点

  • 同步化疗是1.5个月时任何级别淋巴细胞减少的最强预测因素(OR 72.3)。
  • 辅助化疗疗程与12个月时淋巴细胞减少显著相关(OR 1.19)。
  • 6周时3级淋巴细胞减少发生率在同步+辅助组为10%,同步组19%,辅助组0%。

核心结论

  • 同步化疗似乎是WHO II-III级胶质瘤患者放疗后急性淋巴细胞减少严重程度的主要贡献因素,而辅助化疗疗程似乎是持续性淋巴细胞减少的关键因素。

研究设计与样本

  • 回顾性分析2007至2016年接受放疗联合同步和/或辅助化疗的WHO II-III级胶质瘤患者,共151例可评估绝对淋巴细胞计数。

主要发现

  • 6周时3级淋巴细胞减少(ALC<500/mm3)在同步+辅助组9例(10%),同步组6例(19%),辅助组0例(0%)。
  • 12个月时3级淋巴细胞减少在同步+辅助组4例(6%),同步组0例(0%),辅助组3例(17%)。
  • 多因素分析显示,同步化疗(OR 72.3,p<0.001)、女性(OR 10.8,p<0.001)和年龄较大(OR 1.06,p=0.002)是1.5个月时任何级别≥1淋巴细胞减少(ALC<1000/mm3)的最显著预测因素。
  • 年龄较大(OR 1.08,p=0.02)和辅助化疗疗程(OR 1.19,p=0.003)与12个月时级别≥1淋巴细胞减少显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prolonged severe lymphopenia has been shown to persist beyond a year in glioma patients after radiation therapy (RT) with concurrent and adjuvant chemotherapy. This study examines the differential impact of concurrent versus adjuvant chemotherapy on lymphopenia after RT. WHO grade II-III glioma patients who received RT with concurrent and/or adjuvant chemotherapy from 2007 to 2016 were retrospectively analyzed. Concurrent chemotherapy was temozolomide (TMZ), and adjuvant chemotherapy was either TMZ or procarbazine/lomustine/vincristine (PCV). Absolute lymphocyte count (ALC) was analyzed at baseline, 1.5, 3, 6, and 12 months after the start of RT. Univariable and multivariable logistic regression were used to identify the clinical variables in predicting acute or late lymphopenia. There were 151 patients with evaluable ALC: 91 received concurrent and adjuvant TMZ (CRT + ADJ), 32 received only concurrent TMZ (CRT), and 28 received only adjuvant TMZ or PCV (ADJ). There were 9 (10%) versus 6 (19%) versus 0 (0%) cases of grade 3 lymphopenia (ALC < 500/mm3) at 6 weeks and 4 (6%) versus 0 (0%) versus 3 (17%) cases at 12 months in CRT + ADJ, CRT and ADJ groups, respectively. On multivariable analyses, concurrent chemotherapy (odds ratio [OR] 72.3, p < 0.001), female sex (OR 10.8, p < 0.001), and older age (OR 1.06, p = 0.002) were the most significant predictors for any grade ≥ 1 lymphopenia (ALC < 1000/mm3) at 1.5 months. Older age (OR 1.08, p = 0.02) and duration of adjuvant chemotherapy (OR 1.19, p = 0.003) were significantly associated with grade ≥ 1 lymphopenia at 12 months. Thus, concurrent chemotherapy appears as the dominant contributor to the severity of acute lymphopenia after RT in WHO grade II-III glioma patients, and duration of adjuvant chemotherapy appears as the key factor to prolonged lymphopenia.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lin AJ, Campian JL, Hui C, et al. Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol. 2017. PMID: 29143923. doi:10.1007/s11060-017-2668-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。